文献速递淋巴瘤白血病

CD4+ T细胞通过非CD40L依赖机制支持侵袭性慢性淋巴细胞白血病进展

CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
PubMed 文献 · Blood Adv · 2021-01-01

该研究利用Eμ-TCL1小鼠模型(CD4+ T细胞缺失、CD40缺失或CD8+ T细胞缺失)及过继转移实验,探究CD4+ T细胞在慢性淋巴细胞白血病(CLL)中的作用。结果表明CD4+ T细胞对CLL克隆增殖必不可少,且该支持作用不依赖CD40L/CD40通路;CD8+ T细胞则抑制疾病进展。

要点

  • CD4+ T细胞是CLL克隆增殖所必需,缺失或清除后白血病细胞不扩增。
  • CD4+ T细胞的支持作用不依赖CD40L/CD40,且抗原特异性非关键。
  • CD8+ T细胞具有抗肿瘤活性,缺失时疾病加速进展。

核心结论

  • CD4+ T细胞通过非CD40依赖且可能非 cognate 机制支持TCL1小鼠白血病克隆生长。
  • CD8+ T细胞抑制CLL进展。

研究设计与样本

  • 研究使用基因修饰的Eμ-TCL1小鼠:CD4+ T细胞缺失(TCL1+/+AB0)、CD40缺失(TCL1+/+CD40-/-)或CD8+ T细胞缺失(TCL1+/+TAP-/-)。
  • 通过流式细胞术和免疫组化监测疾病出现与进展。
  • 采用过继转移白血病细胞至CD4+ T细胞缺失、CD40L缺失或抗体阻断CD40L/CD40的小鼠中验证。

主要发现

  • 在缺乏或清除CD4+ T细胞的小鼠中,CLL克隆不增殖。
  • TCL1+/+TAP-/-小鼠疾病进展加速,提示CD8+ T细胞抗肿瘤作用。
  • CD4+ T细胞的抗原特异性对CLL发展影响甚微。
  • 在阻断CD40或CD40L-/-小鼠中,白血病克隆仍可增殖;TCL1+/+CD40-/-小鼠发展为明显CLL。

临床怎么用

  • 提示靶向CD4+ T细胞或其支持通路可能成为CLL治疗策略,且CD40L/CD40并非必需靶点。
  • CD8+ T细胞抗肿瘤功能支持免疫治疗策略的开发。

局限性

  • 研究基于Eμ-TCL1小鼠模型,结果需在人类CLL中验证。
  • CD4+ T细胞支持CLL的具体分子机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) is caused by the progressive accumulation of mature CD5+ B cells in secondary lymphoid organs. In vitro data suggest that CD4+ T lymphocytes also sustain survival and proliferation of CLL clones through CD40L/CD40 interactions. In vivo data in animal models are conflicting. To clarify this clinically relevant biological issue, we generated genetically modified Eμ-TCL1 mice lacking CD4+ T cells (TCL1+/+AB0), CD40 (TCL1+/+CD40-/-), or CD8+ T cells (TCL1+/+TAP-/-), and we monitored the appearance and progression of a disease that mimics aggressive human CLL by flow cytometry and immunohistochemical analyses. Findings were confirmed by adoptive transfer of leukemic cells into mice lacking CD4+ T cells or CD40L or mice treated with antibodies depleting CD4 T cells or blocking CD40L/CD40 interactions. CLL clones did not proliferate in mice lacking or depleted of CD4+ T cells, thus confirming that CD4+ T cells are essential for CLL development. By contrast, CD8+ T cells exerted an antitumor activity, as indicated by the accelerated disease progression in TCL1+/+TAP-/- mice. Antigen specificity of CD4+ T cells was marginal for CLL development, because CLL clones efficiently proliferated in transgenic mice whose CD4 T cells had a T-cell receptor with CLL-unrelated specificities. Leukemic clones also proliferated when transferred into wild-type mice treated with monoclonal antibodies blocking CD40 or into CD40L-/- mice, and TCL1+/+CD40-/- mice developed frank CLL. Our data demonstrate that CD8+ T cells restrain CLL progression, whereas CD4+ T cells support the growth of leukemic clones in TCL1 mice through CD40-independent and apparently noncognate mechanisms.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Grioni M, Brevi A, Cattaneo E, et al. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism. Blood Adv. 2021. PMID: 34269799. doi:10.1182/bloodadvances.2020003795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。